Teplizumab
- Product Name
- Teplizumab
- CAS No.
- 876387-05-2
- Chemical Name
- Teplizumab
- Synonyms
- Teplizumab;PRV-031|||MGA-031;Teplizumab (DHC27703);Teplizumab (anti-CD3e);Research Grade Teplizumab;Research Grade Teplizumab(DHC27703);TeplizumabQ: What is Teplizumab Q: What is the CAS Number of Teplizumab
- CBNumber
- CB48081201
- Formula Weight
- 0
- MOL File
- Mol file
Teplizumab Property
- form
- Liquid
- color
- Colorless to light yellow
Teplizumab Chemical Properties,Usage,Production
Uses
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes[1][2].
in vivo
Teplizumab (0.24 mg/kg, i.p.) induces migration of human CD4 T cells to the lamina propria and ablated the treatment effects of the drug on graft survival in NSG mice[2].
| Animal Model: | NOD/SCID IL2γc-/- (NSG) mice (a tolergenic humanized mouse model)[1] |
| Dosage: | 0.24 mg/kg, 5 μg |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Decreased CD4:CD8 ratio in the peripheral blood from 2.03 to 1.01, p < 0.05. Decreased circulating hCD4 cells in the peripheral blood. Decreased in the proportion of T cells in the bone marrow and lung. Increased in the total number of human CD45+ cells infiltrating the lamina propria of the small intestine. |
References
[1] Kevan C Herold, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019 Aug 15;381(7):603-613. DOI:10.1056/NEJMoa1902226
[2] Frank Waldron-Lynch, et al. I Analysis of FcR non-binding anti-CD3 mAb in humanized mice identifies novel human gut tropic cells with regulatory function that are found in patients. Sci Transl Med. 2012 Jan 25;4(118):118ra12. DOI:10.1126/scitranslmed.3003401
[3] Brygida Bisikirska, et al. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest. 2005 Oct;115(10):2904-13. DOI:10.1172/JCI23961